What is HotSpot Therapeutics?
HotSpot Therapeutics is a precision medicine company dedicated to developing first-in-class small molecule therapeutics. At the core of its operations is the proprietary SpotFinder technology, which identifies regulatory hotspots—pockets located away from the active site of a protein that naturally modulate protein function. By targeting these specific sites, the company aims to achieve higher potency and selectivity than traditional drug discovery methods. The firm's pipeline is diverse, spanning kinases, transcription factors, and E3 ligases, with lead programs targeting PKC-theta and S6 kinase. This scientific focus places HotSpot at the intersection of structural biology and medicinal chemistry, providing a robust framework for treating rare diseases, autoimmune conditions, and various forms of cancer.
How much funding has HotSpot Therapeutics raised?
HotSpot Therapeutics has raised a total of $210M across 3 funding rounds:
Series A
$45M
Series B
$65M
Series C
$100M
Series A (2018): $45M with participation from Sofinnova Partners and Atlas Ventures
Series B (2020): $65M led by Brace Pharma Capital LLC, S.R. One , Limited, Tekla Life Sciences Investors, Atlas Venture GmbH, MRL Ventures Fund, Sofinnova Partners, and Solasta Ventures
Series C (2021): $100M supported by Pavilion Capital, Monashee Investment Management, Life Sciences Partners, B Capital Group, and Pivotal Bioventure Partners
Key Investors in HotSpot Therapeutics
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
MRL Ventures Fund
MRL Ventures Fund is a therapeutics-focused corporate venture group that partners with visionary founders to invest in early-stage, preclinical therapeutics companies globally.
What's next for HotSpot Therapeutics?
With the recent infusion of capital, HotSpot Therapeutics is well-positioned to accelerate its clinical development programs and expand its internal pipeline. The company's strategic roadmap involves moving its lead allosteric inhibitors through critical development milestones, further validating the SpotFinder platform's utility in human health. As the firm matures, it is expected to focus on deepening its partnerships and potentially exploring new therapeutic modalities that leverage its unique understanding of protein regulation. The current funding environment provides the necessary runway to sustain long-term research initiatives while maintaining the agility required to navigate the competitive landscape of biotechnology innovation.
See full HotSpot Therapeutics company page
